Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study

J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e539-e542. doi: 10.1111/jdv.17999. Epub 2022 Feb 18.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Humans
  • Methotrexate
  • Omalizumab* / therapeutic use
  • Pemphigoid, Bullous* / drug therapy
  • Steroids

Substances

  • Antibodies, Monoclonal, Humanized
  • Steroids
  • Omalizumab
  • dupilumab
  • Methotrexate